Old Web
English
Sign In
Acemap
>
authorDetail
>
Wen Gu
Wen Gu
Novartis
Ceritinib
Pharmacology
Medicine
Anaplastic lymphoma kinase
Pharmacokinetics
4
Papers
150
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Application of time-dependent modeling for the exposure–efficacy analysis of ceritinib in untreated ALK-rearranged advanced NSCLC patients
2019
Cancer Chemotherapy and Pharmacology
Yvonne Y. Lau
Wen Gu
Yu-Yun Ho
Ying Hong
Xinrui Zhang
Patrick Urban
Show All
Source
Cite
Save
Citations (2)
ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)
2017
Journal of Thoracic Oncology
Byoung Chul Cho
Dong-Wan Kim
Alessandra Bearz
Scott A. Laurie
Mark J. McKeage
Gloria Borra
Keunchil Park
Sang-We Kim
Marwan Ghosn
Andrea Ardizzoni
Evaristo Maiello
Alastair Greystoke
Richard Yu
Karen Osborne
Wen Gu
Jeffrey W. Scott
Vanessa Q. Passos
Yvonne Y. Lau
Anna Wrona
Show All
Source
Cite
Save
Citations (104)
Assessment of drug–drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer
2017
Cancer Chemotherapy and Pharmacology
Yvonne Y. Lau
Wen Gu
Tiffany Lin
Kalyanee Viraswami-Appanna
Can Cai
Jeffrey W. Scott
Michael Shi
Show All
Source
Cite
Save
Citations (12)
Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects
2016
The Journal of Clinical Pharmacology
Yvonne Y. Lau
Wen Gu
Tiffany Lin
Dongweon Song
Richard Yu
Jeffrey W. Scott
Show All
Source
Cite
Save
Citations (32)
1